Kraj: Kanada
Język: angielski
Źródło: Health Canada
DEFERASIROX
TARO PHARMACEUTICALS INC
V03AC03
DEFERASIROX
500MG
TABLET FOR SUSPENSION
DEFERASIROX 500MG
ORAL
15G/50G
Prescription
HEAVY METAL ANTAGONISTS
Active ingredient group (AIG) number: 0151733003; AHFS:
APPROVED
2017-06-26
_TARO-DEFERASIROX (DEFERASIROX) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _PAGE 1 OF 56 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TARO-DEFERASIROX deferasirox Dispersible Tablets for Suspension, 125 mg, 250 mg, or 500 mg, Oral Iron chelating agent Taro Pharmaceuticals Inc. 130 East Drive, Brampton Ontario L6T 1C1 Submission Control No: 268762 Date of Initial Authorization: JUN 26, 2017 Date of Revision: JUN 21, 2023 _TARO-DEFERASIROX (DEFERASIROX) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _PAGE 2 OF 56 _ RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 06/2023 4 DOSAGE AND ADMINISTRATTION; 4.2 Recommended Dose and Dosage Adjustment 06/2023 7 WARNINGS AND PRECAUTIONS 06/2023 7 WARNINGS AND PRECAUTIONS; 7.1.3 Pediatrics 06/2023 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1 . 1 PEDIATRICS ........................................................................................................ 4 1 . 2 GERIATRICS ........................................................................................................ 4 2 CONTRAINDICATIONS................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................... 5 4 DOSAGE AND ADMINISTRATION ............................................................................... 5 4. 1 DOSING CONSIDERATIONS ...................................................................... Przeczytaj cały dokument